0.96
-0.036(-3.60%)
Currency In USD
| Previous Close | 1 |
| Open | 1.02 |
| Day High | 1.02 |
| Day Low | 0.96 |
| 52-Week High | 1.51 |
| 52-Week Low | 0.33 |
| Volume | 780,498 |
| Average Volume | 1.15M |
| Market Cap | 96.75M |
| PE | -3.32 |
| EPS | -0.29 |
| Moving Average 50 Days | 0.98 |
| Moving Average 200 Days | 0.96 |
| Change | -0.04 |
If you invested $1000 in Oncolytics Biotech Inc. (ONCY) 10 years ago, it would be worth $349.28 as of February 21, 2026 at a share price of $0.964. Whereas If you bought $1000 worth of Oncolytics Biotech Inc. (ONCY) shares 5 years ago, it would be worth $292.12 as of February 21, 2026 at a share price of $0.964.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
GlobeNewswire Inc.
Feb 04, 2026 1:50 PM GMT
Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population Company to launch controlled study in second-line KRAS-mutant MSS mCRC with interim data expected by the end of
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders
GlobeNewswire Inc.
Jan 15, 2026 9:01 PM GMT
All resolutions passed, enabling the Company to streamline regulatory and operational processesSAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy comp
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
GlobeNewswire Inc.
Jan 14, 2026 2:00 PM GMT
Appointments strengthen late-stage clinical execution and statistical leadership as the Company advances multiple registration-directed programs in gastrointestinal cancersSAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasda